ArticleClinical ophthalmology (Auckland, N.Z.)2026
Early Clinical Outcomes After the Mix-and-Match Approach of Trifocal and Non-Diffractive EDOF IOL.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate early postoperative visual performance following cataract surgery using the mix-and-match approach with Clareon PanOptix diffractive trifocal and Clareon Vivity non-diffractive extended depth of focus (EDOF) intraocular lenses (IOLs). Patients and Methods: This single-center, retrospective study was conducted between April 2024 and April 2025 and included 27 patients (54 eyes). Each patient underwent bilateral cataract surgery with implantation of a PanOptix IOL in one eye and a Vivity IOL in the fellow eye. Postoperative outcomes were evaluated for up to 1 month after surgery of the second eye. Monocular (PanOptix and Vivity) and binocular (mix-and-match, M-M) uncorrected visual acuity (UCVA) from 5 m to 30 cm, defocus curves (+2.0 D to -4.0 D), mesopic contrast sensitivity with and without glare, and subjective evaluation of photic phenomena (halo) using the ViSU-L Halo & Glare Simulator were assessed. Results: In the M-M group, 73% of patients achieved UCVA of ≤ 0.1 logarithm of the minimum angle of resolution (logMAR) across all distances (5 m to 30 cm). Binocular defocus curves showed visual acuity of ≤ 0.1 logMAR from 0 D to -3.0 D. Area under the log contrast sensitivity functions with or without glare was significantly higher in the M-M group compared to both monocular groups (all P < 0.05). The percentage of patients reporting no halo was highest in the Vivity group (77.8%), followed by the M-M (55.6%) and PanOptix groups (40.7%), and the M-M group showed a significantly higher rate than the PanOptix group (P = 0.0455). Conclusion: Although limited by a short follow-up duration, the combination of PanOptix and Vivity IOL provided a favorable balance between visual acuity, contrast sensitivity, and photic phenomena. Our findings suggest that this mix-and-match approach may serve as a viable option for enhancing visual quality beginning in the early postoperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.